With the right support to scale and bring their innovations to market, biotech start-ups can help transform healthcare across Europe. Many are developing technologies to better manage chronic diseases and address the unmet health needs of an ageing population, driving a much-needed shift toward more personalised, sustainable medicine.
Crucially, biotech seed funding plays a pivotal role in enabling early-stage success, allowing start-ups to navigate the high costs and risks associated with research and development. By showcasing some successful EIT Health-supported biotech start-ups across Europe, this article highlights how biotech is reshaping healthcare and laying the foundation for a healthier future.
The healthcare biotech landscape in Europe
Europe has emerged as a global hub for healthcare biotechnology, driven by a combination of robust academic research institutions, government support, and thriving start-up ecosystems. [1] The European biotech industry is renowned for its focus on solving complex healthcare challenges, ranging from rare diseases to oncology and regenerative medicine. With countries like Germany, France, and the UK leading the charge, the sector boasts more than 3,700 active biotech companies, many of which are focused on healthcare innovation. [2]